"5" . "Hypertension and dyslipidemia"@en . "8"^^ . . "Hypertenze a dyslipidemie" . . "CZ - \u010Cesk\u00E1 republika" . "1"^^ . "P(NS9743), Z(MSM0021620820)" . . . . . . "Hypertenze a dyslipidemie" . "Bl\u00E1ha, Vladim\u00EDr" . "V\u00ED\u0161ek, Jakub" . "11150" . "1212-7299" . . . "[1AC6B5AF38D6]" . . . "RIV/00216208:11150/10:10075519!RIV11-MZ0-11150___" . "Simultaneous appearance of hypertension, diabetes, dyslipidemia and obesity is recently recognised as cardiometabolic risk. Dyslipidemia and hypertension share some common patophysiologic mechanisms, leasing to aterotrombosis, and are frequently similar to other cardiovascular risk factors. Common pathway include increased activity of RAS (renin angiotensin system), which applies both to hypertension and activates as dyslipidemia does endothelial dysfunction, inflammation and thrombosis. It seems that statins slightly, but significantly decrease blood preasure in patients with increased (not normal) ambulatory monitored blood preasure. The choice of suitable antihypertensive agents is essential in the treatment of hypertension and dyslipidemia to reduce the cardiovascular risk (the dose and combination of drugs, namely statins and RAS inhibitors)."@en . . "Intern\u00ED medic\u00EDna pro praxi" . . "262566" . "RIV/00216208:11150/10:10075519" . . . "Hypertenze a dyslipidemie"@cs . "Sou\u010Dasn\u00FD v\u00FDskyt hypertenze, diabetu, dyslipidemie a obezity je nov\u011B ozna\u010Dov\u00E1n pojmem kardiometabolick\u00E9 riziko. Dyslipidemie a hypertenze sd\u00EDlej\u00ED n\u011Bkter\u00E9 spole\u010Dn\u00E9 patofyziologick\u00E9 mechanismy, kter\u00E9 vedou k aterotrombose, a kter\u00E9 jsou \u010Dasto tak\u00E9 obdobn\u00E9 pro jin\u00E9 kardiovaskul\u00E1rn\u00ED rizikov\u00E9 faktory. Spole\u010Dn\u00FDm jmenovatelem je zv\u00FD\u0161en\u00E1 aktivita RAS (renin angiotensin system), kter\u00E1 m\u00E1 jednak d\u016Fle\u017Eitou \u00FAlohu v r\u00E1mci hypertenze, a jednak aktivuje podobn\u011B jako dyslipid\u00E9mie d\u011Bje spojen\u00E9 s dysfunkc\u00ED endotelu, z\u00E1n\u011Btem a trombosou. Zd\u00E1 se, \u017Ee statiny m\u00EDrn\u011B, nicm\u00E9n\u011B signifikantn\u011B sni\u017Euj\u00ED krevn\u00ED tlak u pacient\u016F se zv\u00FD\u0161en\u00FDm (nikoliv norm\u00E1ln\u00EDm) ambulantn\u011B monitorovan\u00FDm krevn\u00EDm tlakem. V l\u00E9\u010Db\u011B hypertenze spojen\u00E9 s dyslipid\u00E9mi\u00ED je v\u00FDb\u011Br vhodn\u00FDch antihypertenziv z\u00E1sadn\u00EDm faktorem v ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika (d\u00E1vka resp. kombinace farmak, zejm\u00E9na typu statin\u016F a inhibitor\u016F aktivace RAS)." . "12" . . "Sou\u010Dasn\u00FD v\u00FDskyt hypertenze, diabetu, dyslipidemie a obezity je nov\u011B ozna\u010Dov\u00E1n pojmem kardiometabolick\u00E9 riziko. Dyslipidemie a hypertenze sd\u00EDlej\u00ED n\u011Bkter\u00E9 spole\u010Dn\u00E9 patofyziologick\u00E9 mechanismy, kter\u00E9 vedou k aterotrombose, a kter\u00E9 jsou \u010Dasto tak\u00E9 obdobn\u00E9 pro jin\u00E9 kardiovaskul\u00E1rn\u00ED rizikov\u00E9 faktory. Spole\u010Dn\u00FDm jmenovatelem je zv\u00FD\u0161en\u00E1 aktivita RAS (renin angiotensin system), kter\u00E1 m\u00E1 jednak d\u016Fle\u017Eitou \u00FAlohu v r\u00E1mci hypertenze, a jednak aktivuje podobn\u011B jako dyslipid\u00E9mie d\u011Bje spojen\u00E9 s dysfunkc\u00ED endotelu, z\u00E1n\u011Btem a trombosou. Zd\u00E1 se, \u017Ee statiny m\u00EDrn\u011B, nicm\u00E9n\u011B signifikantn\u011B sni\u017Euj\u00ED krevn\u00ED tlak u pacient\u016F se zv\u00FD\u0161en\u00FDm (nikoliv norm\u00E1ln\u00EDm) ambulantn\u011B monitorovan\u00FDm krevn\u00EDm tlakem. V l\u00E9\u010Db\u011B hypertenze spojen\u00E9 s dyslipid\u00E9mi\u00ED je v\u00FDb\u011Br vhodn\u00FDch antihypertenziv z\u00E1sadn\u00EDm faktorem v ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika (d\u00E1vka resp. kombinace farmak, zejm\u00E9na typu statin\u016F a inhibitor\u016F aktivace RAS)."@cs . . . "2"^^ . "Hypertenze a dyslipidemie"@cs . "Hypertension and dyslipidemia"@en . . "cardiovascular risk factors; statins; RAS inhibitors; hypertension; Dyslipidemia"@en .